Therapy of Strongyloidiasis with Dithiazanine
| Autor: | J. C. Swartzwelder, J. F. Hebert, P. E. Robertson, J. P. Muhleisen, William W. Frye, C. A. Jones, S. H. Abadie |
|---|---|
| Rok vydání: | 1958 |
| Předmět: |
Anthelmintics
Dithiazanine iodide medicine.medical_specialty biology business.industry Dithiazanine biology.organism_classification medicine.disease Dermatology Strongyloides stercoralis chemistry.chemical_compound Strongyloidiasis chemistry Immunology Internal Medicine medicine Helminths Clinical significance Anthelmintic business Strongyloides ratti medicine.drug |
| Zdroj: | Archives of Internal Medicine. 101:658 |
| ISSN: | 0003-9926 |
| DOI: | 10.1001/archinte.1958.00260150146020 |
| Popis: | Introduction Data presented in this paper provide evidence of the anthelmintic activity and therapeutic effectiveness of 3,3′-diethylthiadicarbocyanine iodide (dithiazanine, Compound 01748) against Strongyloides stercoralis infections in humans and experimental infections with Strongyloides ratti in rats. Prior to this study, a large number of other drugs were evaluated by us for anthelmintic activity against murine and human strongyloidiasis. None of the compounds employed in our previous investigations gave evidence of significant activity or cure of strongyloidiasis in either host. There is a definite need for effective therapeutics for strongyloidiasis. Stoll 1 estimated that there were approximately 35,000,000 infections with S. stercoralis in the world. In one hospital in New Orleans in recent years there have been several hundred patients with strongyloidiasis. Jones 2 has described precisely the clinical significance and characteristics of strongyloidiasis. Frequently the infection persists for many years in man, and on rare occasions it may prove fatal. Interpretation |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|